Weekly Perspectives from Healthcare Experts

A patient became unexpectedly combative during CPR compressions,” recounted Nick Wright, DO, of Virginia Tech Carilion School of Medicine in Roanoke.

Politicians and political candidates should be required to disclose their full, unredacted medical records annually as a prerequisite for entering office,” stated S. Jay Olshansky, PhD, of the University of Illinois Chicago School of Public Health, discussing the sparse health updates since Sen. Mitch McConnell’s (R-Ky.) hospitalization.

The distinction between the drug and the control was remarkably clear,” noted Alan Schatzberg, MD, of Stanford Medicine in California, on a small trial that showed adjunctive ketamine outperformed midazolam for treatment-resistant bipolar depression.

I fear for the survival of this once admirable institution,” said David Nathan, MD, of Massachusetts General Hospital in Boston, reacting to the American Diabetes Association’s review of the events when five researchers were removed from its annual meeting.

Every way you examine the data, there was a benefit,” remarked Ahmad Masri, MD, of Oregon Health & Science University Medical Group in Portland, discussing results from a trial of aficamten (Myqorzo) in symptomatic nonobstructive hypertrophic cardiomyopathy.

There simply are not enough hours in the day,” stated Alexandra Hajduk, PhD, MPH, of Yale School of Medicine in New Haven, Connecticut, on the unrealistic expectation for medical students to publish dozens of peer-reviewed papers during training.

This agent has a very high chance of being game-changing in the clinic,” said Gerald Watts, MD, PhD, of the University of Western Australia in Perth, after a pair of phase III trials showed plozasiran (Redemplo) significantly lowered triglycerides in severe hypertriglyceridemia.

These patients are all truly miserable, so I think this will be a great advance,” stated Victoria Werth, MD, of the University of Pennsylvania in Philadelphia, on the potential of brepocitinib (Lisraya), a selective TYK2/JAK1 inhibitor, to relieve dermatomyositis symptoms.

This study challenges the currently popular ‘strike early and strike strong’ concept,” observed Davide Capodanno, MD, PhD, of the University of Catania in Italy, on trial data showing no immediate clinical benefit from starting PCSK9 inhibitors in the cath lab during a heart attack.

Source link